Literature DB >> 21445612

A Bayesian approach for the estimation of patient compliance based on the last sampling information.

Olivier Barrière1, Jun Li, Fahima Nekka.   

Abstract

Poor adherence to a drug prescription significantly impacts on the efficacy and safety of a planned therapy. The relationship between drug intake and pharmacokinetics (PK) is only partially known. In this work, we focus on the so-called "inverse problem", concerned with the issue of retracing the patient compliance scenario using limited clinical knowledge. Using a reported Pop-PK model of imatinib, and accounting for the variability around its PK parameters, we were able to simulate a whole range of drug concentration values at a specific sampling point for a population of patients with all possible drug compliance profiles. Using a Bayesian decision rule, we developed a methodology for the determination of the associated compliance profile prior to a given sampling value. The adopted approach allows, for the first time, to quantitatively acquire knowledge about the compliance patterns having a causal effect on a given PK. Moreover, using a simulation approach, we were able to evaluate the evolution of success rate of the retracing process in terms of the considered time period before sampling as well as the model-inherited variability. In conclusion, this work allows, from a probability viewpoint, to propose a solution for this inverse problem of compliance determination.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21445612     DOI: 10.1007/s10928-011-9196-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  11 in total

1.  Erratic patient compliance with prescribed drug regimens: target for drug delivery systems.

Authors:  J Urquhart
Journal:  Clin Pharmacol Ther       Date:  2000-04       Impact factor: 6.875

2.  Population one-compartment pharmacokinetic analysis with missing dosage data.

Authors:  Dolors Soy; Stuart L Beal; Lewis B Sheiner
Journal:  Clin Pharmacol Ther       Date:  2004-11       Impact factor: 6.875

3.  A pharmacokinetic formalism explicitly integrating the patient drug compliance.

Authors:  Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-12       Impact factor: 2.745

4.  Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.

Authors:  Emilie Hénin; Michel Tod; Véronique Trillet-Lenoir; Catherine Rioufol; Brigitte Tranchand; Pascal Girard
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  A probabilistic approach for the evaluation of pharmacological effect induced by patient irregular drug intake.

Authors:  Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-25       Impact factor: 2.745

6.  Do we need full compliance data for population pharmacokinetic analysis?

Authors:  P Girard; L B Sheiner; H Kastrissios; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1996-06

7.  Discrimination between rival dosing histories.

Authors:  E N Jonsson; J R Wade; G Almqvist; M O Karlsson
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

8.  Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories.

Authors:  Bernard Vrijens; Gäbor Vincze; Paulus Kristanto; John Urquhart; Michel Burnier
Journal:  BMJ       Date:  2008-05-14

9.  Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies.

Authors:  Bernard Vrijens; Els Goetghebeur
Journal:  Stat Med       Date:  2004-02-28       Impact factor: 2.373

10.  Estimation of population pharmacokinetic parameters in the presence of non-compliance.

Authors:  Song Mu; Thomas M Ludden
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

View more
  8 in total

1.  Variability and singularity arising from poor compliance in a pharmacokinetic model II: the multi-oral case.

Authors:  Lisandro J Fermín; Jacques Lévy-Véhel
Journal:  J Math Biol       Date:  2016-07-18       Impact factor: 2.259

2.  Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs.

Authors:  Evelina Cardoso; Chantal Csajka; Marie P Schneider; Nicolas Widmer
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

3.  Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.

Authors:  Ayyappa Chaturvedula; Michael J Fossler; Craig W Hendrix
Journal:  J Clin Pharmacol       Date:  2013-11-30       Impact factor: 3.126

4.  Compliance spectrum as a drug fingerprint of drug intake and drug disposition.

Authors:  Olivier Barrière; Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-19       Impact factor: 2.745

5.  Methods to detect non-compliance and reduce its impact on population PK parameter estimates.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky; Valerie Cosson; Nicolas Frey; Franziska Schaedeli Stark
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-06-21       Impact factor: 2.745

6.  Variability and singularity arising from poor compliance in a pharmacokinetic model I: the multi-IV case.

Authors:  Pierre-Emmanuel Lévy Véhel; Jacques Lévy Véhel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-30       Impact factor: 2.745

7.  Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women.

Authors:  Rebecca N Burns; Craig W Hendrix; Ayyappa Chaturvedula
Journal:  J Clin Pharmacol       Date:  2015-02-04       Impact factor: 3.126

8.  Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children.

Authors:  Junjie Ding; Matthew E Coldiron; Bachir Assao; Ousmane Guindo; Daniel Blessborn; Markus Winterberg; Rebecca F Grais; Alena Koscalova; Celine Langendorf; Joel Tarning
Journal:  Clin Pharmacol Ther       Date:  2019-12-31       Impact factor: 6.875

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.